Published in Clin Exp Immunol on January 01, 2000
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol (2002) 1.30
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 1.29
The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer (2001) 0.88
Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART. J Clin Immunol (2002) 0.81
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72
Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (1994) 5.68
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04
Host factors and the pathogenesis of HIV-induced disease. Nature (1996) 4.96
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 4.43
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood (1991) 1.80
Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 1.61
The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis (1993) 1.55
Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med (1998) 1.50
Cytokine modulation of HIV expression. Semin Immunol (1993) 1.48
High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS (1994) 1.29
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol (1998) 1.20
Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 1.07
The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.04
Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS (1993) 1.00
Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses (1997) 0.99
Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis (1994) 0.95
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Hum Retroviruses (1997) 0.87
Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response. Clin Exp Immunol (1998) 0.83
Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol (1993) 0.79
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology (1994) 3.05
HIV infection does not require endocytosis of its receptor, CD4. Cell (1988) 2.88
In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol (1990) 2.70
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology (1987) 2.30
Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer (2001) 2.26
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
AIDS pathogenesis: HIV envelope and its interaction with cell proteins. Immunol Today (1990) 2.21
Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int (1999) 2.14
A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med (1991) 2.10
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. J Infect Dis (1992) 1.90
Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol (1991) 1.84
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia (2009) 1.80
Human T cell leukaemia/lymphoma virus and blood donation. BMJ (1993) 1.79
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.73
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med (1994) 1.72
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.66
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS) J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.57
Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS (1997) 1.57
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood (1996) 1.52
Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study Group. Clin Infect Dis (1995) 1.51
Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study. Am J Epidemiol (1992) 1.46
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ (1990) 1.45
Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer (2002) 1.44
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer (2000) 1.43
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer (2004) 1.43
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol (2010) 1.41
Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentation. Clin Oncol (R Coll Radiol) (1995) 1.41
Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood (1998) 1.39
Antiphospholipid antibodies cross-reacting with erythrocyte membranes. A case report. Clin Exp Rheumatol (1992) 1.38
Epidemic Kaposi's sarcoma in Italy, a country with intravenous drug abusers as the major group at risk for AIDS: report of 60 cases. AIDS (1989) 1.38
The gp120 envelope of HIV-1 binds peptides in a similar manner to human leukocyte antigens. AIDS (1995) 1.38
Nested polymerase chain reaction for diagnosis and monitoring treatment response in AIDS patients with tuberculous meningitis. AIDS (1995) 1.37
Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol (1986) 1.37
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer (2009) 1.35
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection (2009) 1.33
HLA-associated susceptibility to acquired immunodeficiency syndrome in Italian patients with human-immunodeficiency-virus infection. Lancet (1986) 1.31
Inactivation of HIV by nonoxynol-9. Lancet (1988) 1.30
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol (2002) 1.30
TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS (1994) 1.29
Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med (1997) 1.28
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis (2001) 1.28
HIV seroprevalence among 304 female prostitutes from four Italian towns. AIDS (1989) 1.27
The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol (2001) 1.26
Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis. Clin Exp Immunol (1990) 1.26
HTLV-III serology distinguishes atypical and endemic Kaposi's sarcoma in Africa. Lancet (1985) 1.25
Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? Clin Infect Dis (1997) 1.24
Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. Clin Exp Immunol (1985) 1.24
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol (1998) 1.20
Epidemiology of cryptosporidiosis among European AIDS patients. Genitourin Med (1996) 1.20
TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med (2003) 1.20
Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis (1992) 1.20
AIDS-defining diseases in 250 HIV-infected patients; a comparative study of clinical and autopsy diagnoses. AIDS (1992) 1.20
Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS (1998) 1.19
Replication of hepatitis C virus in B lymphocytes (CD19+) Blood (1999) 1.18
Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood (1999) 1.17
HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4. Lancet (1990) 1.16
Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol (1988) 1.15
Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol (2007) 1.14
Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J Infect Dis (1996) 1.14
Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol (2000) 1.14
Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. A two-step mechanism involving the gp120 molecule. J Clin Invest (1997) 1.14
Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis (2000) 1.13
Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol (2005) 1.13
Concurrent hydatid disease and cryptococcosis in a 16-year-old girl. Med J Aust (1981) 1.11
Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther (2006) 1.09
Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies. AIDS (1993) 1.09
Antigen test versus reverse transcriptase assay for detecting HIV. Lancet (1987) 1.09
Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer (2000) 1.08
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection (2009) 1.08
Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur Heart J (1988) 1.08
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol (2007) 1.08
Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis. Clin Exp Immunol (1993) 1.08
Detection of rifampin resistance in Mycobacterium tuberculosis by double gradient-denaturing gradient gel electrophoresis. Antimicrob Agents Chemother (1999) 1.08
The relevance of HIV env/CD4 interactions to the pathogenesis of acquired immune deficiency syndrome. J Acquir Immune Defic Syndr (1989) 1.07
CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med (1998) 1.07